Shares of Divi's Labs declined 3.85 per cent to hit a low of Rs 6,621.50 on BSE.Divi's Laboratories Ltd on Friday reported a 35 per cent year-on-year (YoY) rise in consolidated net profit at Rs 689 crore for the second quarter ended September 2025, compared to Rs 510 crore in the same period last year.
The Hyderabad-based pharmaceutical company's consolidated revenue from operations grew 16 per cent YoY to Rs 2,715 crore in Q2 FY26, against Rs 2,338 crore reported in the September 2024 quarter. Total income for the quarter stood at Rs 2,860 crore, up from Rs 2,444 crore a year ago.
Profit before tax (PBT) for the quarter rose to Rs 912 crore from Rs 722 crore in the corresponding period last year. The company recorded foreign exchange gains of Rs 63 crore during the quarter, compared to Rs 29 crore in the year-ago period.
For the half year ended September 2025, Divi's reported a consolidated total income of Rs 5,389 crore, higher than Rs 4,640 crore in the same period of the previous year. PBT for the first half of FY26 increased to Rs 1,645 crore from Rs 1,326 crore last year, while profit after tax (PAT) rose to Rs 1,234 crore from Rs 940 crore. Forex gains for the six-month period stood at Rs 102 crore, up from Rs 28 crore a year earlier.
Despite the earnings growth, shares of Divi's Laboratories declined 3.85 per cent to hit a low of Rs 6,621.50 on BSE.
As of September 2025, promoters held a 51.89 per cent stake in the pharma firm.
Exam reforms: Tech titan Nandan Nilekani picked by PM Modi to fix national public examination system 
'Tax officers struggled for own land': Nirmala Sitharaman slams laidback attitude of govt depts
CBDT issues new crypto reporting guidance: No new tax, but exchanges must track and report all transactions
Did Cockroach Janta Party's 'Chalo Sansad' 2.0 threat trigger Dharmendra Pradhan's resignation? What we know so far
'Will discharge my responsibilities with complete humility': Pralhad Joshi after being appointed Education Minister
AI Data Centers, Aerospace & Gas Turbines: What's Powering Indo-MIM's Future Growth?
Best Healthcare Stocks: Gaurang Shah's Outlook On Apollo Hospitals, Fortis & The Manipal Health IPO
Is Indo-MIM's IPO Valuation Justified? Here's Why The Company Sees Strong Growth Ahead
Treasury Bills Explained: Why T-Bills Are One Of The Safest Short-Term Investment Options
FDs vs Markets: Where Should You Keep Your Short-Term Money?
Gland Pharma stock: Price target of Rs 3,250 likely in medium term, says analyst 
Metal recycling stocks to buy: Gravita, Pondy Oxides, Jain Resource among top picks
TRIL shares: Should you average the falling stock? Here's 'fixed and final' stop loss
Adani Power: 45 GW target, Rs 2 lakh crore capex plan among conference call highlights 
ITC Hotels, Chalet, Ventive, IHCL, SAMHI: Hotel stocks to buy despite travel disruptions
Beyond mutual funds: Why analysts see SBI Funds' alternative asset business as a long-term growth engine
'Ashamed of it...': Manoj Muntashir calls Adipurush his biggest mistake, seeks country's forgiveness Exam reforms: Tech titan Nandan Nilekani picked by PM Modi to fix national public examination system 'Tax officers struggled for own land': Nirmala Sitharaman slams laidback attitude of govt depts
Delhi targets traffic bottlenecks on Aruna Asaf Ali Marg with ₹1.97 crore elevated road study
